{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:50:16Z","timestamp":1792176616202,"version":"4.4.0"},"reference-count":169,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer is the most common malignant neoplasm in women. Despite progress to date, 700,000 women worldwide died of this disease in 2020. Apparently, the prognostic markers currently used in the clinic are not sufficient to determine the most appropriate treatment. For this reason, great efforts have been made in recent years to identify new molecular biomarkers that will allow more precise and personalized therapeutic decisions in both primary and recurrent breast cancers. These molecular biomarkers include genetic and post-transcriptional alterations, changes in protein expression, as well as metabolic, immunological or microbial changes identified by multiple omics technologies (e.g., genomics, epigenomics, transcriptomics, proteomics, glycomics, metabolomics, lipidomics, immunomics and microbiomics). This review summarizes studies based on omics analysis that have identified new biomarkers for diagnosis, patient stratification, differentiation between stages of tumor development (initiation, progression, and metastasis\/recurrence), and their relevance for treatment selection. Furthermore, this review highlights the importance of clinical trials based on multiomics studies and the need to advance in this direction in order to establish personalized therapies and prolong disease-free survival of these patients in the future.<\/jats:p>","DOI":"10.3389\/fonc.2023.1292046","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:07:54Z","timestamp":1702984074000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Multiomics insights on the onset, progression, and metastatic evolution of breast cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Lucia","family":"Alvarez-Frutos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Barriuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Palacios-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Senovilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.632079","article-title":"Advanced approaches to breast cancer classification and diagnosis","volume":"11","author":"Zubair","year":"2020","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1524-4741.2009.00822.x","article-title":"Breast cancer subtypes as defined by the estrogen receptor (Er), progesterone receptor (Pr), and the human epidermal growth factor receptor 2 (Her2) among women with invasive breast cancer in California, 1999-2004","volume":"15","author":"Parise","year":"2009","journal-title":"Breast J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (Serms) and selective estrogen receptor degraders (Serds) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S336643","article-title":"The role of progesterone receptors in breast cancer","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"Her2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/path.4280","article-title":"Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes","volume":"232","author":"Lehmann","year":"2014","journal-title":"J Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41379-020-00704-7","article-title":"Prognostic and predictive parameters in breast pathology: A pathologist's primer","volume":"34","author":"Allison","year":"2021","journal-title":"Mod Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/life11111131","article-title":"New insight to overcome tumor resistance: an overview from cellular to clinical therapies","volume":"11","author":"Mitola","year":"2021","journal-title":"Life (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/bcr1528","article-title":"High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer","volume":"8","author":"Rennstam","year":"2006","journal-title":"Breast Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12282-015-0617-8","article-title":"Genomic tumor evolution of breast cancer","volume":"23","author":"Sato","year":"2016","journal-title":"Breast Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005457","article-title":"Transcriptomics technologies","volume":"13","author":"Lowe","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1186\/s12885-018-4621-1","article-title":"Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer","volume":"18","author":"Zoppino","year":"2018","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-021-01116-4","article-title":"Ultra-high-performance liquid chromatography high-resolution mass spectrometry variants for metabolomics research","volume":"18","author":"Perez de Souza","year":"2021","journal-title":"Nat Methods"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2011.12.001","article-title":"Glycans as cancer biomarkers","volume":"1820","author":"Adamczyk","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7550","article-title":"Metabolomics: available results, current research projects in breast cancer, and future applications","volume":"25","author":"Claudino","year":"2007","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/metabo9050102","article-title":"Breast cancer metabolomics: from analytical platforms to multivariate data analysis","volume":"9","author":"Silva","year":"2019","journal-title":"A Review Metabolites"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2015.12.013","article-title":"Trans-omics: how to reconstruct biochemical networks across multiple 'Omic' Layers","volume":"34","author":"Yugi","year":"2016","journal-title":"Trends Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/biom12081021","article-title":"Molecular biomarkers in cancer","volume":"12","author":"Sarhadi","year":"2022","journal-title":"Biomolecules"},{"key":"B25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13058-020-01345-z","article-title":"Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses","volume":"22","author":"Fumagalli","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17225","article-title":"Characterization of potential driver mutations involved in human breast cancer by computational approaches","volume":"8","author":"Rajendran","year":"2017","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10719-021-10001-3","article-title":"Serum N-glycan profiles differ for various breast cancer subtypes","volume":"38","author":"Vreeker","year":"2021","journal-title":"Glycoconj J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwn095","article-title":"A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression","volume":"18","author":"Abd Hamid","year":"2008","journal-title":"Glycobiology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1021\/ac100131e","article-title":"Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: A potential methodology for cancer-biomarker discovery","volume":"82","author":"Alley","year":"2010","journal-title":"Anal Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201200126","article-title":"Proteomic analysis and abrogated expression of O-glcnacylated proteins associated with primary breast cancer","volume":"13","author":"Champattanachai","year":"2013","journal-title":"Proteomics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cca.2015.10.032","article-title":"Diagnostic approach to breast cancer patients based on target metabolomics in saliva by liquid chromatography with tandem mass spectrometry","volume":"452","author":"Takayama","year":"2016","journal-title":"Clin Chim Acta"},{"key":"B33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11306-021-01823-1","article-title":"An integrative approach based on Gc-Qms and Nmr metabolomics data as a comprehensive strategy to search potential breast cancer biomarkers","volume":"17","author":"Silva","year":"2021","journal-title":"Metabolomics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40170-022-00289-6","article-title":"Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer","volume":"10","author":"An","year":"2022","journal-title":"Cancer Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169330","article-title":"1h nmr metabolomics reveals association of high expression of inositol 1, 4, 5 trisphosphate receptor and metabolites in breast cancer patients","volume":"12","author":"Singh","year":"2017","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2016.05.022","article-title":"High levels of sphingolipids in human breast cancer","volume":"204","author":"Nagahashi","year":"2016","journal-title":"J Surg Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2013.09.004","article-title":"Biophysics of cell membrane lipids in cancer drug resistance: implications for drug transport and drug delivery with nanoparticles","volume":"65","author":"Peetla","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3894","article-title":"Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression","volume":"71","author":"Hilvo","year":"2011","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14048047","article-title":"Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients","volume":"14","author":"Qiu","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bbcan.2019.04.001","article-title":"The power of small changes: comprehensive analyses of microbial dysbiosis in breast cancer","volume":"1871","author":"Parida","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01235-16","article-title":"The microbiota of breast tissue and its association with breast cancer","volume":"82","author":"Urbaniak","year":"2016","journal-title":"Appl Environ Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188873","article-title":"A comprehensive analysis of breast cancer microbiota and host gene expression","volume":"12","author":"Thompson","year":"2017","journal-title":"PLoS One"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/srep30751","article-title":"The microbiome of aseptically collected human breast tissue in benign and Malignant disease","volume":"6","author":"Hieken","year":"2016","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/cas.13463","article-title":"Breast cancer: the translation of big genomic data to cancer precision medicine","volume":"109","author":"Low","year":"2018","journal-title":"Cancer Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133046","article-title":"Breast cancer genomics: primary and most common metastases","volume":"14","author":"Bennett","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2012.881","article-title":"Differential proteomic analysis of pathway biomarkers in human breast cancer by integrated bioinformatics","volume":"4","author":"Fu-Jun","year":"2012","journal-title":"Oncol Lett"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12105","article-title":"Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up","volume":"11","author":"Saldova","year":"2017","journal-title":"Mol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)43295-9","article-title":"Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked glcnac","volume":"259","author":"Torres","year":"1984","journal-title":"J Biol Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.7b00595","article-title":"Deep learning accurately predicts estrogen receptor status in breast cancer metabolomics data","volume":"17","author":"Alakwaa","year":"2018","journal-title":"J Proteome Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00242-14","article-title":"Microbiota of human breast tissue","volume":"80","author":"Urbaniak","year":"2014","journal-title":"Appl Environ Microbiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cells12151945","article-title":"The emerging role of the microbiota in breast cancer progression","volume":"12","author":"Bernardo","year":"2023","journal-title":"Cells"},{"key":"B52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12885-021-09074-y","article-title":"Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women","volume":"22","author":"Esposito","year":"2022","journal-title":"BMC Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6360","DOI":"10.1038\/s41598-021-85899-8","article-title":"Correlation between family history and characteristics of breast cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"B54","article-title":"[Deafness due to topical neomycin (Author's transl)]","volume":"24","author":"Quante","year":"1976","journal-title":"HNO"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2, and P53 in patients with mutations in Brca1 and Brca2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3396","article-title":"Survival in hereditary breast cancer associated with germline mutations of Brca2","volume":"17","author":"Verhoog","year":"1999","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-12-0649","article-title":"Genomic and epigenomic cross-talks in the regulatory landscape of Mirnas in breast cancer","volume":"11","author":"Samantarrai","year":"2013","journal-title":"Mol Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.06.006","article-title":"Breast cancer classification by proteomic technologies: current state of knowledge","volume":"40","author":"Lam","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10259","article-title":"Proteomic maps of breast cancer subtypes","volume":"7","author":"Tyanova","year":"2016","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/srep18517","article-title":"Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer","volume":"6","author":"Michaut","year":"2016","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3574","article-title":"In situ desi-msi lipidomic profiles of breast cancer molecular subtypes and precursor lesions","volume":"80","author":"Santoro","year":"2020","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010147","article-title":"Human plasma metabolomics for biomarker discovery: targeting the molecular subtypes in breast cancer","volume":"13","author":"Diaz-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1021\/pr200685r","article-title":"Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (Gpam) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling","volume":"11","author":"Brockmoller","year":"2012","journal-title":"J Proteome Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12935","article-title":"Identification of ganglioside Gm2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes","volume":"107","author":"Shin","year":"2016","journal-title":"Cancer Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00951","article-title":"Distinct microbial signatures associated with different breast cancer types","volume":"9","author":"Banerjee","year":"2018","journal-title":"Front Microbiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/bcr1867","article-title":"Breast cancer metastasis: A microrna story","volume":"10","author":"Negrini","year":"2008","journal-title":"Breast Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.stem.2010.06.012","article-title":"Micrornas as regulators of differentiation and cell fate decisions","volume":"7","author":"Ivey","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061559","article-title":"Unraveling the genomic-epigenomic interaction landscape in triple negative and non-triple negative breast cancer","volume":"12","author":"Wu","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12967-021-03076-x","article-title":"A novel immune subtype classification of er-positive, Pr-negative and Her2-negative breast cancer based on the genomic and transcriptomic landscape","volume":"19","author":"Xie","year":"2021","journal-title":"J Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/pr500676x","article-title":"Label-free proteomic analysis of breast cancer molecular subtypes","volume":"13","author":"Panis","year":"2014","journal-title":"J Proteome Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-022-28524-0","article-title":"Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes","volume":"13","author":"Asleh","year":"2022","journal-title":"Nat Commun"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7155","article-title":"Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer","volume":"7","author":"Fan","year":"2016","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0415-9","article-title":"A joint analysis of metabolomics and genetics of breast cancer","volume":"16","author":"Tang","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"17831","DOI":"10.1038\/s41598-017-17897-8","article-title":"Metabolomics reveals novel blood plasma biomarkers associated to the brca1-mutated phenotype of human breast cancer","volume":"7","author":"Roig","year":"2017","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215364","article-title":"Transcriptomic profiling of breast cancer cells induced by tumor-associated macrophages generates a robust prognostic gene signature","volume":"14","author":"Long","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13148-015-0159-0","article-title":"The integrative epigenomic-transcriptomic landscape of Er positive breast cancer","volume":"7","author":"Gao","year":"2015","journal-title":"Clin Epigenet"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.07.002","article-title":"The epigenomic revolution in breast cancer: from single-gene to genome-wide next-generation approaches","volume":"187","author":"Davalos","year":"2017","journal-title":"Am J Pathol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"16787","DOI":"10.1038\/s41598-021-96340-5","article-title":"Survival analysis in breast cancer using proteomic data from four independent datasets","volume":"11","author":"Osz","year":"2021","journal-title":"Sci Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3711","article-title":"Proteomic portrait of human breast cancer progression identifies novel prognostic markers","volume":"72","author":"Geiger","year":"2012","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13058-017-0905-7","article-title":"Proteomic profiling of breast cancer metabolism identifies Shmt2 and Asct2 as prognostic factors","volume":"19","author":"Bernhardt","year":"2017","journal-title":"Breast Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030992","article-title":"Proteomic analyses reveal high expression of decorin and endoplasmin (Hsp90b1) are associated with breast cancer metastasis and decreased survival","volume":"7","author":"Cawthorn","year":"2012","journal-title":"PLoS One"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2018.05.003","article-title":"Re-evaluating E-cadherin and Beta-catenin: A pan-cancer proteomic approach with an emphasis on breast cancer","volume":"188","author":"Borcherding","year":"2018","journal-title":"Am J Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100220","article-title":"Proteogenomic analysis of breast cancer transcriptomic and proteomic data, using de novo transcript assembly: genome-wide identification of novel peptides and clinical implications","volume":"21","author":"Hari","year":"2022","journal-title":"Mol Cell Proteomics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1074\/mcp.M600171-MCP200","article-title":"A serum glycomics approach to breast cancer biomarkers","volume":"6","author":"Kirmiz","year":"2007","journal-title":"Mol Cell Proteomics"},{"key":"B85","article-title":"A sage (Serial analysis of gene expression) view of breast tumor progression","volume":"61","author":"Porter","year":"2001","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13148-016-0201-x","article-title":"Global histone modification profiling reveals the epigenomic dynamics during Malignant transformation in a four-stage breast cancer model","volume":"8","author":"Zhao","year":"2016","journal-title":"Clin Epigenet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201800446","article-title":"Olfm4 expression in ductal carcinoma in situ and in invasive breast cancer cohorts by a swath-based proteomic approach","volume":"19","author":"Valo","year":"2019","journal-title":"Proteomics"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01304-1","article-title":"Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: A case-control study nested within the French E3n cohort","volume":"124","author":"Jobard","year":"2021","journal-title":"Br J Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-016-0289-9","article-title":"Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis","volume":"8","author":"Huang","year":"2016","journal-title":"Genome Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.1c00019","article-title":"Early breast cancer detection using untargeted and targeted metabolomics","volume":"20","author":"Wei","year":"2021","journal-title":"J Proteome Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2012.08644.x","article-title":"Lipid metabolism in cancer","volume":"279","author":"Santos","year":"2012","journal-title":"FEBS J"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.0c00038","article-title":"Triple negative breast cancer detection using Lc-Ms\/Ms lipidomic profiling","volume":"19","author":"Eghlimi","year":"2020","journal-title":"J Proteome Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1186\/bcr899","article-title":"Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression","volume":"6","author":"Abba","year":"2004","journal-title":"Breast Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.semcancer.2017.03.007","article-title":"Transcriptomic and genomic features of invasive lobular breast cancer","volume":"44","author":"Desmedt","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1038\/s41467-019-10929-z","article-title":"Landscape of transcriptomic interactions between breast cancer and its microenvironment","volume":"10","author":"Fox","year":"2019","journal-title":"Nat Commun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00583-9","article-title":"In silico transcriptomic mapping of integrins and immune activation in basal-like and Her2+ Breast cancer","volume":"44","author":"Rojas","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0500-y","article-title":"Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis","volume":"16","author":"Orlando","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2989-3","article-title":"The circadian gene Cry2 is associated with breast cancer aggressiveness possibly via epigenomic modifications","volume":"36","author":"Mao","year":"2015","journal-title":"Tumour Biol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129762","article-title":"Plasma proteomic profiling in hereditary breast cancer reveals a brca1-specific signature: diagnostic and functional implications","volume":"10","author":"Scumaci","year":"2015","journal-title":"PloS One"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27973","article-title":"Integration of metabolomic and transcriptomic data reveals metabolic pathway alteration in breast cancer and impact of related signature on survival","volume":"234","author":"Luo","year":"2019","journal-title":"J Cell Physiol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-015-8484-x","article-title":"Comprehensive lipid profiling of plasma in patients with benign breast tumor and breast cancer reveals novel biomarkers","volume":"407","author":"Yang","year":"2015","journal-title":"Anal Bioanal Chem"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28155898","article-title":"Identification of bacterial metabolites modulating breast cancer cell proliferation and epithelial-mesenchymal transition","volume":"28","author":"Ujlaki","year":"2023","journal-title":"Molecules"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15856","article-title":"Breast cancer subtypes predict the preferential site of distant metastases: A seer based study","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van 't Veer","year":"2002","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2553","article-title":"Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer","volume":"65","author":"Weigelt","year":"2005","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4048","article-title":"Genomic, transcriptomic, and proteomic profiling of metastatic breast cancer","volume":"27","author":"Akcakanat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8802","article-title":"Genes associated with breast cancer metastatic to bone","volume":"24","author":"Smid","year":"2006","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0062-0","article-title":"Central role of snail1 in the regulation of Emt and resistance in cancer: A target for therapeutic intervention","volume":"33","author":"Kaufhold","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/nature03799","article-title":"Genes that mediate breast cancer metastasis to lung","volume":"436","author":"Minn","year":"2005","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20843","article-title":"Mapk, Nfkappab, and Vegf signaling pathways regulate breast cancer liver metastasis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.588136","article-title":"Prognosis and genomic landscape of liver metastasis in patients with breast cancer","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf4408","article-title":"The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile","volume":"7","author":"Berthelet","year":"2021","journal-title":"Sci Adv"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2131","article-title":"Atad2 is a novel cofactor for Myc, overexpressed and amplified in aggressive tumors","volume":"69","author":"Ciro","year":"2009","journal-title":"Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/bcr1849","article-title":"Derlin-1 is overexpressed in human breast carcinoma and protects cancer cells from endoplasmic reticulum stress-induced apoptosis","volume":"10","author":"Wang","year":"2008","journal-title":"Breast Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.24059","article-title":"Nek2a contributes to tumorigenic growth and possibly functions as potential therapeutic target for human breast cancer","volume":"113","author":"Wang","year":"2012","journal-title":"J Cell Biochem"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200585","article-title":"A high-resolution integrated map spanning the sdhd gene at 11q23: A 1.1-Mb Bac Contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region","volume":"9","author":"Baysal","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"B119","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The Atm-Chk2 and Atr-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1647","article-title":"Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in Aurora, the breast international group (Big) molecular screening initiative","volume":"11","author":"Aftimos","year":"2021","journal-title":"Cancer Discov"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810901","article-title":"Identification of a gene panel predictive of triple-negative breast cancer response to neoadjuvant chemotherapy employing transcriptomic and functional validation","volume":"23","author":"Vishnubalaji","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02028","article-title":"Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer","volume":"9","author":"Foulds","year":"2018","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usz254","article-title":"Proteomic analysis of inflammatory biomarkers associated with breast cancer recurrence","volume":"185","author":"Bera","year":"2020","journal-title":"Mil Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-03-0118","article-title":"Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung","volume":"10","author":"Mehrotra","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"75ra25","DOI":"10.1126\/scitranslmed.3001875","article-title":"Breast cancer methylomes establish an epigenomic foundation for metastasis","volume":"3","author":"Fang","year":"2011","journal-title":"Sci Transl Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6922","article-title":"Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes","volume":"7","author":"Messier","year":"2016","journal-title":"Oncotarget"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13629","article-title":"Metabolomics research on potential role for 9-cis-retinoic acid in breast cancer progression","volume":"109","author":"Wu","year":"2018","journal-title":"Cancer Sci"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0662-8","article-title":"High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer","volume":"122","author":"Kawashima","year":"2020","journal-title":"Br J Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0537","article-title":"A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and Beta-catenin axes","volume":"11","author":"Parida","year":"2021","journal-title":"Cancer Discov"},{"key":"B131","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1038\/s41467-020-16967-2","article-title":"Breast cancer colonization by fusobacterium nucleatum accelerates tumor growth and metastatic progression","volume":"11","author":"Parhi","year":"2020","journal-title":"Nat Commun"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215306","article-title":"The predictive and prognostic role of Ras-Raf-Mek-Erk pathway alterations in breast cancer: revision of the literature and comparison with the analysis of cancer genomic datasets","volume":"14","author":"Rocca","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102768","article-title":"Functional proteomic profiling of triple-negative breast cancer","volume":"10","author":"Gromova","year":"2021","journal-title":"Cells"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt224","article-title":"Unraveling the role of Kiaa1199, a novel endoplasmic reticulum protein, in cancer cell migration","volume":"105","author":"Evensen","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-194","article-title":"Functional proteomic analysis reveals the involvement of Kiaa1199 in breast cancer growth, motility and invasiveness","volume":"14","author":"Jami","year":"2014","journal-title":"BMC Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201700465","article-title":"Immunopeptidomic profiling of Hla-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens","volume":"18","author":"Ternette","year":"2018","journal-title":"Proteomics"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103107","article-title":"Caatlas: an immunopeptidome atlas of human cancer","volume":"24","author":"Yi","year":"2021","journal-title":"iScience"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00614-0","article-title":"Comprehensive metabolomics expands precision medicine for triple-negative breast cancer","volume":"32","author":"Xiao","year":"2022","journal-title":"Cell Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/metabo8030041","article-title":"Unbiased lipidomic profiling of triple-negative breast cancer tissues reveals the association of sphingomyelin levels with patient disease-free survival","volume":"8","author":"Purwaha","year":"2018","journal-title":"Metabolites"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01229-06","article-title":"Small interfering Rna screens reveal enhanced cisplatin cytotoxicity in tumor cells having both Brca network and Tp53 disruptions","volume":"26","author":"Bartz","year":"2006","journal-title":"Mol Cell Biol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the pi3k pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2008.61","article-title":"A synthetic lethal sirna screen identifying genes mediating sensitivity to a parp inhibitor","volume":"27","author":"Turner","year":"2008","journal-title":"EMBO J"},{"key":"B143","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2008.01.001","article-title":"Identification of Cdk10 as an important determinant of resistance to endocrine therapy for breast cancer","volume":"13","author":"Iorns","year":"2008","journal-title":"Cancer Cell"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810539","article-title":"Comprehensive transcriptomic and proteomic analyses identify a candidate gene set in cross-resistance for endocrine therapy in breast cancer","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1021\/pr2008187","article-title":"Proteomic approach reveals Fkbp4 and S100a9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer","volume":"11","author":"Yang","year":"2012","journal-title":"J Proteome Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13216","article-title":"Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: A novel metabolomics approach","volume":"16","author":"Diaz","year":"2022","journal-title":"Mol Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.9b00316","article-title":"Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients","volume":"18","author":"Debik","year":"2019","journal-title":"J Proteome Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020314","article-title":"Effect of estrogen receptor status on circulatory immune and metabolomics profiles of Her2-positive breast cancer patients enrolled for neoadjuvant targeted chemotherapy","volume":"12","author":"Vignoli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205055","article-title":"Metabolomics by nmr combined with machine learning to predict neoadjuvant chemotherapy response for breast cancer","volume":"14","author":"Cardoso","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"key":"B151","article-title":"Transcriptomic and functional pathway features were associated with survival after pathological complete response to neoadjuvant chemotherapy in breast cancer","volume":"10","author":"Takeshita","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.708052","article-title":"Nmr-based metabolomics analysis predicts response to neoadjuvant chemotherapy for triple-negative breast cancer","volume":"8","author":"He","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0603","article-title":"Personalized medicine for patients with advanced cancer in the phase I program at Md Anderson: validation and landmark analyses","volume":"20","author":"Tsimberidou","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0591","article-title":"Gene signature evaluation as a prognostic tool: challenges in the design of the mindact trial","volume":"3","author":"Bogaerts","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"B155","article-title":"Individualization of therapy using mammaprint: from development to the mindact trial","volume":"4","author":"Mook","year":"2007","journal-title":"Cancer Genomics Proteomics"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3222","article-title":"Clinical application of the 70-gene profile: the Mindact trial","volume":"26","author":"Cardoso","year":"2008","journal-title":"J Clin Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.09.016","article-title":"The Eortc 10041\/Big 03-04 Mindact trial is feasible: results of the pilot phase","volume":"47","author":"Rutgers","year":"2011","journal-title":"Eur J Cancer"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised mindact trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.014","article-title":"Outcome without any adjuvant systemic treatment in stage I Er+\/Her2- breast cancer patients included in the mindact trial","volume":"33","author":"Lopes Cardozo","year":"2022","journal-title":"Ann Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01371","article-title":"Standard anthracycline based versus docetaxel-capecitabine in early high clinical and\/or genomic risk breast cancer in the Eortc 10041\/Big 3-04 Mindact phase iii trial","volume":"38","author":"Delaloge","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000512467","article-title":"Transferring mindact to daily routine: implementation of the 70-gene signature in luminal early breast cancer - results from a prospective registry of the Austrian group medical tumor therapy (Agmt)","volume":"17","author":"Westphal","year":"2022","journal-title":"Breast Care (Basel)"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2006.n.051","article-title":"Tailorx: trial assigning individualized options for treatment (Rx)","volume":"7","author":"Sparano","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4794","article-title":"Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: A secondary analysis of the tailorx randomized clinical trial","volume":"6","author":"Sparano","year":"2020","journal-title":"JAMA Oncol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa148","article-title":"Race, ethnicity, and clinical outcomes in hormone receptor-positive, Her2-negative, node-negative breast cancer in the randomized Tailorx trial","volume":"113","author":"Albain","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00491-x","article-title":"Multiomics in primary and metastatic breast tumors from the Aurora us network finds microenvironment and epigenetic drivers of metastasis","volume":"4","author":"Garcia-Recio","year":"2023","journal-title":"Nat Cancer"},{"key":"B169","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1292046\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:08:00Z","timestamp":1702984080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1292046\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":169,"alternative-id":["10.3389\/fonc.2023.1292046"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1292046","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"article-number":"1292046"}}